EBS

Emergent BioSolutions Inc. NYSE

Healthcare ·Drug Manufacturers - Specialty & Generic ·US · emergentbiosolutions.com

$8.54

Mkt Cap $441.0M

52w Low $4.71 41.0% of range 52w High $14.06

50d MA $8.54 200d MA $9.60

P/E (TTM) 8.6x

EV/EBITDA 4.9x

P/B 0.9x

Debt/Equity 1.1x

ROE 10.1%

P/FCF 4.2x

RSI (14) —

ATR (14) —

Beta 2.36

50d MA $8.54

200d MA $9.60

Avg Volume 843.9K

About

Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging h…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Apr 30, 2026	AMC	-0.25	0.21	+184.0%	8.23	+9.2%	+2.9%	+3.8%	+6.0%	—	—	—
Feb 26, 2026	AMC	0.11	-0.43	-490.9%	11.10	-26.1%	-26.6%	-19.0%	-19.6%	-21.0%	-24.0%	—
Oct 29, 2025	AMC	-0.12	1.06	+983.3%	9.40	+15.5%	+36.6%	+32.8%	+11.6%	+7.3%	+10.0%	—
Aug 6, 2025	AMC	-0.26	0.16	+161.5%	6.03	+8.5%	+36.7%	+42.1%	+35.3%	+47.8%	+45.8%	—
May 7, 2025	AMC	0.49	0.71	+44.9%	4.74	+14.6%	+34.2%	+19.2%	+23.2%	+24.1%	+19.0%	—
Mar 3, 2025	AMC	-0.35	0.05	+114.3%	6.83	-18.6%	-6.4%	-15.1%	-14.5%	-15.5%	-17.7%	—
Nov 6, 2024	AMC	0.49	1.37	+179.6%	9.20	+24.2%	+19.6%	+27.9%	+30.1%	+18.4%	+8.4%	—
Aug 6, 2024	AMC	-0.97	-2.32	-139.2%	9.86	-35.5%	-42.0%	-14.8%	-28.1%	-32.4%	-31.2%	—
May 1, 2024	AMC	-0.86	0.59	+168.6%	1.93	+52.8%	+71.0%	+101.6%	+106.2%	+128.0%	+128.5%	—
Mar 6, 2024	AMC	-0.33	-0.77	-133.3%	3.26	-16.3%	-15.0%	-17.5%	-14.1%	-28.5%	-31.3%	—
Dec 11, 2023	AMC	-0.12	-1.44	-1100.0%	2.12	+0.0%	-1.4%	+8.0%	+19.3%	+12.3%	+10.4%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Mar 9	HC Wainwright & Co.	Maintains	Buy → Buy	—	$8.29	$8.20	-1.1%	+0.7%	+1.2%	-1.3%	-1.9%	-2.7%
Dec 16	HC Wainwright & Co.	Maintains	Buy → Buy	—	$12.33	$12.25	-0.6%	-1.1%	-1.0%	-0.2%	+0.7%	+3.9%
Sep 3	HC Wainwright & Co.	Maintains	Buy → Buy	—	$8.21	$8.20	-0.1%	-4.6%	-7.1%	-7.7%	-7.9%	+0.6%
Apr 1	HC Wainwright & Co.	Maintains	Buy → Buy	—	$4.86	$4.82	-0.8%	-2.5%	+6.4%	-0.6%	-7.0%	-8.6%
Mar 21	HC Wainwright & Co.	Maintains	Buy → Buy	—	$5.73	$5.69	-0.7%	-0.2%	+0.0%	-4.0%	-9.8%	-14.1%
Mar 4	HC Wainwright & Co.	Maintains	Buy → Buy	—	$6.83	$5.56	-18.6%	-6.4%	-15.1%	-14.5%	-15.5%	-17.7%
Jan 21	HC Wainwright & Co.	Maintains	Buy → Buy	—	$9.88	$9.97	+0.9%	+3.4%	+10.0%	+16.2%	+18.0%	+13.3%
Jan 10	HC Wainwright & Co.	Maintains	Buy → Buy	—	$10.09	$9.82	-2.7%	-2.1%	-6.7%	-7.2%	-5.6%	-1.2%
Nov 7	Benchmark	Maintains	Buy → Buy	—	$9.20	$11.43	+24.2%	+19.6%	+27.9%	+30.1%	+18.4%	+8.4%
Sep 13	Rodman & Renshaw	Maintains	Buy → Buy	—	$7.63	$7.56	-0.9%	+3.1%	-5.0%	-9.8%	-9.6%	-8.4%
Aug 16	Benchmark	Maintains	Buy → Buy	—	$8.66	$10.00	+15.5%	+24.0%	+39.7%	+11.3%	+21.1%	+9.7%
Aug 9	Benchmark	Maintains	Buy → Buy	—	$8.40	$8.32	-1.0%	-15.6%	-20.6%	-19.3%	-9.9%	+3.1%
Jul 3	Benchmark	Maintains	Buy → Buy	—	$7.49	$7.62	+1.7%	+0.7%	+5.9%	+8.5%	+16.4%	+24.2%
Jul 2	Benchmark	Maintains	Buy → Buy	—	$7.06	$7.28	+3.1%	+6.1%	+6.8%	+12.3%	+15.2%	+23.5%
Jun 24	Benchmark	Maintains	Buy → Buy	—	$6.52	$6.48	-0.6%	+3.8%	+5.7%	+0.6%	+7.1%	+4.6%
Jun 21	Benchmark	Maintains	Buy → Buy	—	$6.47	$6.54	+1.1%	+0.8%	+4.6%	+6.5%	+1.4%	+7.9%
Jun 20	Benchmark	Maintains	Buy → Buy	—	$6.06	$6.23	+2.8%	+6.8%	+7.6%	+11.7%	+13.7%	+8.3%
Apr 11	Benchmark	Maintains	Buy → Buy	—	$2.23	$2.24	+0.4%	-1.8%	-7.6%	-11.2%	-12.6%	-14.8%
Mar 7	Benchmark	Upgrade	Hold → Buy	—	$3.26	$2.73	-16.3%	-15.0%	-17.5%	-14.1%	-28.5%	-31.3%
Aug 29	Benchmark	Downgrade	Buy → Hold	—	$4.42	$4.21	-4.8%	-7.9%	+2.7%	+6.1%	+14.9%	+9.0%
May 31	Benchmark	Maintains	Buy → Buy	—	$8.22	$8.22	+0.0%	+3.8%	-0.2%	+0.2%	-3.8%	-2.6%
May 19	Benchmark	Maintains	Buy → Buy	—	$8.64	$8.64	+0.0%	-5.4%	-0.8%	+1.2%	-2.5%	-5.7%
Apr 10	Benchmark	Upgrade	Hold → Buy	—	$10.56	$11.15	+5.6%	+17.2%	+25.1%	+17.3%	+19.5%	+12.2%
Mar 17	JP Morgan	Downgrade	Neutral → Underweight	—	$9.65	$8.80	-8.8%	-15.9%	-16.4%	-15.3%	-19.3%	-18.5%
Nov 10	Benchmark	Downgrade	Buy → Hold	—	$12.85	$13.49	+5.0%	+16.7%	+22.5%	+4.7%	+3.6%	-5.1%
Nov 9	Chardan Capital	Maintains	Buy → Buy	—	$19.73	$17.39	-11.9%	-34.9%	-24.0%	-20.2%	-31.8%	-32.5%
Sep 12	Cowen & Co.	Maintains	Market Perform → Market Perform	—	$25.07	$25.10	+0.1%	-0.1%	-8.8%	-9.4%	-8.0%	-8.5%
May 4	Wells Fargo	Maintains	Equal Weight → Equal Weight	—	$33.37	$33.09	-0.8%	+1.4%	-3.3%	-5.7%	-8.1%	-8.9%
Apr 29	Chardan Capital	Maintains	Buy → Buy	—	$36.61	$34.61	-5.5%	-11.6%	-7.7%	-8.8%	-7.5%	-11.8%
Mar 10	Wells Fargo	Maintains	Equal Weight → Equal Weight	—	$42.20	$41.87	-0.8%	-6.3%	-13.6%	-12.3%	-9.5%	-7.3%
Nov 10	Chardan Capital	Maintains	Buy → Buy	—	$35.09	$34.37	-2.1%	+0.0%	+1.0%	+5.3%	+8.0%	+16.4%
Nov 8	Benchmark	Downgrade	Buy → Hold	—	$33.11	$33.42	+0.9%	+4.3%	+6.0%	+6.0%	+7.0%	+11.6%
May 5	Argus	Downgrade	Buy → Hold	—	$59.10	$58.79	-0.5%	+3.2%	+3.0%	+4.3%	+1.3%	-0.5%
Apr 30	Chardan Capital	Maintains	Buy → Buy	—	$63.15	$61.82	-2.1%	-3.4%	-2.5%	-6.4%	-3.4%	-3.6%
Apr 7	Benchmark	Maintains	Buy → Buy	—	$79.25	$79.55	+0.4%	-0.5%	-0.8%	-2.4%	-4.3%	-8.2%
Feb 24	Chardan Capital	Upgrade	Neutral → Buy	—	$93.49	$98.00	+4.8%	+5.7%	+3.9%	+2.7%	+9.3%	+6.2%
Feb 19	Chardan Capital	Downgrade	Buy → Neutral	—	$117.06	$106.98	-8.6%	-12.0%	-16.5%	-20.1%	-15.6%	-17.0%
Jan 8	Wells Fargo	Downgrade	Overweight → Equal Weight	—	$100.77	$97.08	-3.7%	-3.5%	-1.9%	+2.6%	+6.8%	+5.2%
Jul 31	Chardan Capital	Maintains	Buy → Buy	—	$97.02	$103.63	+6.8%	+14.7%	+21.6%	+26.4%	+38.6%	+30.9%
Jul 17	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$99.47	$99.92	+0.5%	+4.8%	+2.6%	-5.4%	-5.5%	-10.6%
Jun 8	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$86.91	$75.02	-13.7%	-21.0%	-20.1%	-18.1%	-21.6%	-20.9%
May 6	Argus	Maintains	Buy → Buy	—	$79.51	$79.50	-0.0%	-0.0%	-0.3%	+1.5%	+6.3%	+2.5%
May 1	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$73.95	$76.67	+3.7%	+6.4%	+7.5%	+7.5%	+7.5%	+7.2%
May 1	Chardan Capital	Maintains	Buy → Buy	—	$73.95	$76.67	+3.7%	+6.4%	+7.5%	+7.5%	+7.5%	+7.2%
Apr 30	Wells Fargo	Maintains	Overweight → Overweight	—	$73.95	$74.00	+0.1%	+0.0%	+6.4%	+7.5%	+7.5%	+7.5%
Feb 25	Wells Fargo	Maintains	Overweight → Overweight	—	$61.44	$62.66	+2.0%	-2.5%	-4.9%	-10.0%	-4.5%	-4.3%
Sep 12	Guggenheim	Maintains	Buy → Buy	—	$54.41	$55.05	+1.2%	-0.5%	-4.4%	-2.3%	-2.0%	-2.1%
Sep 4	Wells Fargo	Upgrade	Market Perform → Outperform	—	$50.14	$52.71	+5.1%	+11.7%	+13.1%	+11.8%	+12.9%	+14.1%
Nov 2	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$63.86	$63.90	+0.1%	+1.5%	+5.0%	+7.9%	+8.9%	+5.8%
Nov 2	Goldman Sachs	Upgrade	Neutral → Buy	—	$63.86	$63.90	+0.1%	+1.5%	+5.0%	+7.9%	+8.9%	+5.8%

Recent Filings

8-K · 1.01 ! Medium

Emergent Biosolutions, Inc. -- 8-K 1.01: Financing / Debt Agreement

Emergent BioSolutions secured a $150 million credit agreement, providing additional liquidity to support operations and strategic initiatives while potentially reducing reliance on equity financing.

Apr 17

8-K · 5.02 !!! Very High

Emergent Biosolutions, Inc. -- 8-K 5.02: Executive Change

Emergent BioSolutions appoints John D. Fowler as Class II director effective March 1, 2026, adding board expertise to support the company's strategic direction.

Mar 3

8-K · 7.01 ! Medium

Emergent Biosolutions, Inc. -- 8-K 7.01: Regulation FD Disclosure

Emergent Biosolutions will host a February 26 earnings call to discuss Q4 and full-year 2025 results, with presentation materials available on its website.

Feb 26

Data updated apr 25, 2026 6:19am · Source: massive.com